Liquidia (NASDAQ:LQDA) Releases Earnings Results, Beats Estimates By $0.11 EPS

Key Points

• Liquidia beat Q1 earnings estimates by a wide margin, reporting $0.52 EPS versus the $0.41 consensus and revenue of $132.87 million versus expectations of $119.44 million.
• YUTREPIA is driving rapid commercial growth, with management citing about 4,500 unique prescriptions, roughly 3,750 patients started, and $129.9 million in net product sales, helping push the company to a >$500 million annualized run rate.
• The company is now profitable and well capitalized, posting its third straight profitable quarter with about $52.9 million in net income and $71.2 million in adjusted EBITDA, while ending the quarter with $222.8 million in cash.

Liquidia (NASDAQ:LQDA - Get Free Report) announced its earnings results on Monday. The company reported $0.52 EPS for the quarter, topping analysts' consensus estimates of $0.41 by $0.11, Briefing.com reports. The firm had revenue of $132.87 million during the quarter, compared to analysts' expectations of $119.44 million. Liquidia had a negative return on equity of 209.33% and a negative net margin of 43.53%.The business's revenue for the quarter was up 4187.1% on a year-over-year basis.

Here are the key takeaways from Liquidia's conference call:

• YUTREPIA adoption is accelerating — management reports ~4,500 unique prescriptions, ~3,750 patients started since launch and Q1 net product sales of $129.9M, claiming the company drove all market growth in the quarter and a >$500M annualized run rate in under one year.
• Profitable, cash-generating commercial model — Liquidia recorded its third consecutive profitable quarter (Q1 net income ~$52.9M, adjusted EBITDA ~$71.2M) and ended the quarter with $222.8M in cash, enabling reinvestment into sales, manufacturing and clinical programs from operating cash flow.
• Pipeline and clinical expansion underway — the company is recruiting ASCENT cohort B to support switching evidence, advancing the pivotal INSPIRE Phase III for L606 (twice-daily treprostinil), and exploring additional indications (IPF, PPF, PH-COPD, scleroderma-associated Raynaud’s) to materially expand franchise value.
• Ongoing litigation and legal uncertainty — management acknowledged parallels between the company’s patent litigation and the recent Hikma v. Amarin arguments; while confident, timing and outcomes remain uncertain and could materially affect competitive dynamics if unfavorable.

Liquidia Trading Up 25.6%

NASDAQ:LQDA opened at $53.13 on Tuesday. The stock has a market capitalization of $4.72 billion, a price-to-earnings ratio of -64.01 and a beta of 0.41. Liquidia has a 52 week low of $11.85 and a 52 week high of $53.93. The company has a quick ratio of 1.84, a current ratio of 2.01 and a debt-to-equity ratio of 2.97. The firm has a 50 day moving average of $37.66 and a 200 day moving average of $35.04.

Analyst Ratings Changes

A number of analysts recently weighed in on LQDA shares. Jefferies Financial Group reissued a "buy" rating and issued a $60.00 price objective on shares of Liquidia in a research report on Monday. Wall Street Zen upgraded Liquidia from a "hold" rating to a "buy" rating in a research report on Saturday, March 7th. BTIG Research upped their target price on Liquidia from $50.00 to $59.00 and gave the company a "buy" rating in a research note on Monday. Lifesci Capital upgraded Liquidia to a "strong-buy" rating in a report on Thursday, March 5th. Finally, Zacks Research raised Liquidia from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, May 5th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Sell rating to the company's stock. According to MarketBeat, Liquidia currently has a consensus rating of "Moderate Buy" and an average target price of $46.78.

Insiders Place Their Bets

In other news, CEO Roger Jeffs sold 32,744 shares of the company's stock in a transaction on Monday, April 13th. The stock was sold at an average price of $38.37, for a total transaction of $1,256,387.28. Following the transaction, the chief executive officer directly owned 1,137,599 shares of the company's stock, valued at approximately $43,649,673.63. This represents a 2.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Stephen M. Bloch sold 62,550 shares of the stock in a transaction on Friday, March 27th. The shares were sold at an average price of $35.94, for a total value of $2,248,047.00. Following the sale, the director owned 2,188,935 shares of the company's stock, valued at approximately $78,670,323.90. This represents a 2.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 628,820 shares of company stock valued at $24,801,008. 25.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in LQDA. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Liquidia in the 4th quarter valued at about $25,000. NewEdge Advisors LLC acquired a new position in shares of Liquidia in the second quarter worth about $25,000. Tower Research Capital LLC TRC boosted its stake in shares of Liquidia by 281.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company's stock worth $83,000 after acquiring an additional 4,927 shares in the last quarter. Ensign Peak Advisors Inc acquired a new stake in shares of Liquidia during the 4th quarter valued at about $235,000. Finally, Rafferty Asset Management LLC acquired a new stake in shares of Liquidia during the 4th quarter valued at about $247,000. Hedge funds and other institutional investors own 64.54% of the company's stock.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reported first-quarter 2026 earnings of $0.52 per share, well above estimates, while revenue of $132.87 million also topped forecasts. The company said YUTREPIA generated about $130 million in net product sales, helping deliver a third consecutive quarter of profitability and another cash increase. Article: Liquidia Corporation Reports First Quarter 2026 Financial Results
• Positive Sentiment: Needham & Company raised its price target on Liquidia to $70 from $54 and reiterated a buy rating, signaling confidence in further upside after the earnings beat. Article: Needham price target increase
• Positive Sentiment: BTIG Research also lifted its price target to $59 from $50 and kept a buy rating, adding to the bullish analyst momentum around the stock. Article: BTIG price target increase
• Neutral Sentiment: Liquidia’s earnings call transcript and presentation may provide more detail on YUTREPIA sales, launch trends, and upcoming pipeline programs, but they are not new catalysts by themselves. Article: Q1 2026 Earnings Call Transcript Article: Q1 2026 Results Presentation
• Neutral Sentiment: The company also disclosed a short-interest update showing 0 shares reported short, which does not appear to be a meaningful market driver. Article: Short interest update
• Negative Sentiment: Recent insider selling by the CEO could create some caution for investors, even though it does not offset the stronger operational news. Article: Insider selling

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company's lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).